-
Mashup Score: 0
Standardizing the definition of intermediate-risk (IR) non-muscle-invasive bladder cancer (NMIBC), which is a heterogeneous disease, is critical for appropriate management of patients. The International Bladder Cancer Group recommends classification of IR NMIBC tumors and personalized management bas …
Source: PubMedCategories: Dental, Latest Headlines, Onc News and JournalsTweet
-
Mashup Score: 0
Standardizing the definition of intermediate-risk (IR) non-muscle-invasive bladder cancer (NMIBC), which is a heterogeneous disease, is critical for appropriate management of patients. The International Bladder Cancer Group recommends classification of IR NMIBC tumors and personalized management bas …
Source: PubMedCategories: Dental, Latest Headlines, Onc News and JournalsTweet-
Pubmed
-
-
Mashup Score: 3
This trial confirms the superiority of the combination melphalan and prednisone plus thalidomide over melphalan and prednisone alone for prolonging survival in very elderly patients with newly diagnosed myeloma. Toxicity was acceptable.
Source: PubMedCategories: Latest Headlines, Partners & KOLsTweet-
A trip down memory lane- and another great trial by the IFM group. IFM 01/01 (enrolled from 2002-06) Melphalan/pred (MP) vs MP+thalidomide (MPT) in patients aged ≥75 with MM Primary Endpoint: Overall Survival, 29 mo for MP vs 44 mo for MPT #mmsm https://t.co/PhBfc1DgBZ https://t.co/DVm2gdT1ZK
-
-
Mashup Score: 4
Cartesian Therapeutics and National Institute of Neurological Disorders and Stroke of the National Institutes of Health.
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
Congrats to Volkan Granit and entire study team. Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study. #BCMA #tcellrx https://t.co/2reiazDC8h
-
-
Mashup Score: 0
Despite high choline content in egg yolks, healthy participants consuming 4 eggs daily showed no significant increase in TMAO or platelet reactivity. However, choline bitartrate supplements providing comparable total choline raised both TMAO and platelet reactivity, demonstrating that the form and s …
Source: PubMedCategories: Latest Headlines, Partners & KOLsTweet-
Interesting. Science is science. Dietary Choline Supplements, but Not Eggs, Raise Fasting TMAO Levels in Participants with Normal Renal Function: A … https://t.co/GkE5bHWlxl @megynkelly
-
-
Mashup Score: 7
Financial Toxicity in Oncology, More Unanswered Questions
Source: PubMedCategories: Latest Headlines, Partners & KOLsTweet-
"An integral part of improving value is less reliance on unvalidated surrogate end points and recognition that these end points can mislead and often inherently predispose to more therapy and as a result more financial toxicity" @RBeechPharmD @kczmj https://t.co/z652dNrq2S https://t.co/29E8BZhAOm
-
-
Mashup Score: 1Randomized comparison of cooked and noncooked diets in patients undergoing remission induction therapy for acute myeloid leukemia - PubMed - 2 year(s) ago
In patients treated in a PE, a neutropenic diet did not prevent major infection or death.
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
RCT cooked & noncooked (neutropenic) diets in Pts undergoing remission AML Tx [2008] Gardner et al. @JCO_@ASCO https://t.co/mlAkx4Vowy #SuppOnc #IDonc #leusm #AMLsm
-
-
Mashup Score: 0
Implementation of the Trust pathway in accordance with the BOAST guidelines along with staff education has standardized the practice at our Trust. It saved approximately 63 hours of trauma theatre time for the six-month data collection period. Our findings also suggest that this has favourable outco …
Source: PubMedCategories: Latest Headlines, OrthopedicsTweet-
New research shows that our BOAST guidelines for the early management of distal forearm fractures in children saved approximately 63 hours of trauma theatre time over six months. Read the full report here: https://t.co/AojxAGCy9x https://t.co/xkkoNAIHo2
-
-
Mashup Score: 1Combination of ciprofloxacin/celecoxib as a novel therapeutic strategy for ALS - PubMed - 2 year(s) ago
This study supports the safety and tolerability of PrimeC in ALS. Biomarker analyses suggest early evidence of a biological effect. A placebo-controlled trial is required to disentangle the biomarker results from natural progression and to evaluate the efficacy of PrimeC for the treatment of ALS. Su …
Source: PubMedCategories: Latest Headlines, Rare DiseaseTweet-
RT @rpavaneijk: @onein300 @Jeanc9orf72 @alsadvocacy Yes exactly, I really like the approach in this trial: https://t.co/8hUmvsry93. They at…
-
-
Mashup Score: 2
Intensive low-density lipoprotein cholesterol lowering with a proprotein convertase subtilisin/kexin type 9 inhibitor combined with statin does not appear to increase the risk of new or worsening cancer events.
Source: PubMedCategories: Cardiologists, Latest HeadlinesTweet-
RT @Drlipid: PCSK9i showing no cancer risk - see https://t.co/6EIAJp9Ayy
-
Thoughts